Address: Egide Van Ophemstraat 110 B, 1180, Brussels, Belgium
Tel: +32 (0)2 370 48 11
Web: http://www.astrazeneca.be/
AstraZeneca wants more than just a world leader in drug development.
As one of the leading pharmaceutical companies, our efforts focused on turning good ideas into innovative and effective medicines that make a difference in key areas of health.
We work with all interested parties (patients, physicians, academia, R & D departments, health care managers, …) and develop with them new therapeutic approaches that lead to the development of new drugs, better focused on the conditions for improving the quality of life and the welfare of patients.
AstraZeneca Belgium is active in:
AnesthesiaCardiologyDiabetesGastroenterologyInfectiologyOncologyPneumologyPsychiatry & Neurology
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters –…
The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found…
Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all,…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
See our Cookie Privacy Policy Here
